Member Info for JimiHendrix

Haha I can’t believe that…

Either way I think we could very likely see 35-45p next week. Market makers are gradually walking the shareprice up to a higher level, really strong demand for these shares now with the company on the verge of making some serious money and changing the lives of millions of new borns. POC test on top of that of course, and exciting future developments in personalised medicine.

Yes looking very strong here now, expecting this to move back up swiftly.

Yes I agree, sales news or further rollout is what is needed next.

This bit implies to me that NHS rollout (sales) might not be absolutely as imminent as we have all been thinking...

"The service will initially be introduced at neonatal units at Manchester University NHS Foundation Trust, but NHS England has stated that the NHS Genomic Medicine Service Alliance and the NHS intend to explore how the technology could be launched as part of a clinical service through the NHS Genomic Medicine Service."

"The service will initially be introduced at neonatal units at Manchester University NHS Foundation Trust, but NHS England has stated that the NHS Genomic Medicine Service Alliance and the NHS intend to explore how the technology could be launched as part of a clinical service through the NHS Genomic Medicine Service."

I expect other NHS units to take up the AIHL test very soon indeed, I think NHS Liverpool may already be in the process.

I'm also expecting sales in Spain for the Covid POC test, they have a very attractive market over there and covid cases are on the up. First POC sales were made in March soon after the distributor deals were signed, so I'm also expecting further sales from all distributors and new distributor deals announced this month.

Yes it was on LinkedIn, they weren't sure if it was going to be on local or regional news, either way fantastic.

It should push up this afternoon with this buying. Market makers not making it easy to buy, it keeps going to NT / no price available.

Looking forward to the ITV news this evening and the clearly building media coverage and excitement around AIHL.

Very nice presentation!

Covid cases surging in German (600k new cases yesterday) and France (about 200k again).

Need to sign up to Investor Meet.

It's a shame the short tracker website doesn't update on the actual day, seems to have a few days delay.

That was on Friday's peak to 31p, they probably closed it Monday or Tuesday morning around 24p.

If not then very odd.

https://inews.co.uk/news/health/simple-genetic-test-newborns-prevent-deafness-1543811

The instant that toddler Khobi Jerome hears the opening notes of any song from Frozen, she’s up on her feet ready to perform, pulling her mother up to join her. But Khobi would have been left profoundly deaf for life, had she not been given a world-first bedside genetic test minutes after she was born in Manchester.

Her mother Mary Kho-Ogden shakes her head in disbelief as she watches her 21-month-old daughter: “I can’t imagine Khobi without her hearing. She is so very ‘out there’ and babbles to everyone. She would be a completely different baby from the one she is now.”

The fact that Khobi can hear normally is because she was given a simple cheek swab test immediately after her birth, which 20 minutes later indicated that Khobi carries a genetic variant that meant she would go instantly and profoundly deaf if given the antibiotic gentamicin.

This is routinely given within an hour of birth to newborns in intensive care. So nurses substituted it for an equally effective alternative.

Khobi’s hearing was saved by Genedrive – the world’s first genetic bedside test to be used in an emergency setting – which was put through a real-life trial at St Mary’s Hospital, Manchester, part of Manchester University NHS Foundation Trust.

The test was done on 751 newborns in 2020, to see whether it was accurate and reliable when used outside a lab, and whether it could be carried out by non-medical staff.

The answer to both questions was a resounding, yes. The test is so simple it can be done easily alongside other screening procedures and accuracy is more than 95 per cent.

Around 90,000 newborn babies in the UK are treated with gentamicin, which guidelines from the National Institute for Health and Care Excellence say should be administered within the first hour.

Researchers have known for 25 years, through studies on people with cystic fibrosis, that the antibiotic could lead to deafness caused by a genetic variant which affects 1 in 500 people. Testing for it has until now taken days.

The plan is to roll out the trial to other Greater Manchester hospitals in the next couple of months and eventually across the NHS. More than 180 babies a year in the UK could be saved from deafness.

In addition to saving families from the emotional anguish, the success of the PALoH (Pharmacogenetics to Avoid Loss of Hearing) study will save the NHS an estimated £5m a year (including the cost of the test) in cochlear implantations and other hospital costs, according to health economists making up part of the team....

....More on the link above

Yes this settles any doubt... fantastic!

The MIB was initiated in October 2021, prior the announcement of the pivotal Manchester clinical publication (PALOH), published 21 March 2022. The PALOH publication addresses several observations in the MIB including the evolution of the design of the Genedrive® MT-RNR1 test, the excellent adoption levels of the device with in a NICU setting, and the ability to perform the test within the 1-hour admission window required. There is no other test currently available that fulfils the requirements of MT-RNR1 testing in an acute setting. Details of the test can be found on the Company's website at https://www.genedrive.com/assays/rnr1-product.php

Might see the BBC run a story on AIHL, it’s pretty ground breaking technology.

One expert noted that around 7% of all newborn babies have antibiotics in the first 28 days after birth, with most eligible for the Genedrive MT-RNR1 ID test. Two experts said that there were a lot of other people who need aminoglycosides who may also benefit from the test.

Seems to me that as long as the NHS staff are trained properly to carry the test out then there will be no issues, as per the trials. Now it is installed in Manchester it will be a clear example to other units how well it works, and will speak for itself.

Yes and it's worth noting that the expert who had the concerns was the only expert out of 3 experts, who was unfamiliar with the technology.

General comments
One expert noted that around 7% of all newborn babies have antibiotics in the first 28 days after birth, with most eligible for the Genedrive MT-RNR1 ID test. Two experts said that there were a lot of other people who need aminoglycosides who may also benefit from the test.

All 3 experts agreed that the technology would be in addition to standard care because there is no similar technology that can rapidly detect the m.1555A>G variant.

One expert unfamiliar with the technology felt that the 1-hour treatment window in an acute setting, recognised as a quality metric, is already difficult to achieve. So adding 26 minutes for m.1555A>G testing could make this unachievable in practice. Another expert, who was familiar with the technology, said that in well-trained and well-motivated units the technology could fit into the time window. But they were concerned about performance of the test when implemented nationally (because of training and use at different sites) and about potential delays in antibiotic administration. One expert also pointed out potential issues with test failures and implementation. But another noted that, although there had been test failures with the initial system, recent updates had improved results.

In terms of current research, 1 expert said that the PALOH V2 implementation initiative will mean from early 2022 the technology will start being used in NICUs across Greater Manchester. They suggested that future research should assess its accuracy, costs compared with benefits, false negative or false positive rates in routine clinical practice, and the test's reliability across the NHS and in populations other than newborn babies.

All the experts felt that NICE guidance on rapid point of care testing using Genedrive MT-RNR1 ID test would be useful. But one thought that clinicians would feel that the immediate risk of delaying antibiotic treatment in an acute setting would outweigh the longer-term risk of aminoglycoside-induced hearing loss in a few people.

Some goods and some less good...

Level of innovation
All 3 experts agreed that Genedrive MT-RNR1 ID test is an innovative technology. They said the technology would be novel in the NHS because of the speed of results. Two experts noted that in practice there is currently no way of assessing MT-RNR1 genotype in an acute setting, so Genedrive MT-RNR1 ID test presents an innovative advancement.

Potential patient impact
All 3 experts said that the main potential benefit is reducing aminoglycoside exposure in people who carry the m.1555A>G variant, so avoiding them having aminoglycoside-induced hearing loss.

One expert said that the effects of aminoglycosides on cells in newborn babies may be different to that in adults or children, and that the effects of the m.1555A>G variant may depend on the extent of exposure to aminoglycosides.

All 3 experts agreed that Genedrive MT-RNR1 ID test would benefit people with the m.1555A>G variant. One expert mentioned it would particularly benefit babies admitted to the newborn intensive care unit (NICU). They said it had the potential to change the current care pathway and clinical outcomes.

Two experts agreed that reducing the number of aminoglycoside-induced hearing loss cases would reduce the individual and societal burden of hearing loss. Examples given by 1 expert were: preventing the need for cochlear implantation, and reducing hospital visits and prelingual deafness support.

Potential system impact
Two experts said that Genedrive MT-RNR1 ID test would reduce aminoglycoside-induced hearing loss. One said it could prevent hundreds of cases each year in the UK based on the current 90,000 annual admissions. However, 1 expert said that the potential to use the test was very limited in an acute setting, and that it could even cause harm by delaying antibiotic administration in acute severe infection.

The 3 experts had differing viewpoints about the initial capital and possible future costs associated with the technology. One suggested costs would increase because of increased staff workload in acute settings. But 2 said that any implementation costs for the technology were justified if they were outweighed by the lifetime costs relating to hearing loss. One expert recommended a formal economic analysis and noted that, although the technology itself was simple, implementation would be complex because of the need to communicate the results across the healthcare system. One expert noted that there is no direct standard care comparator but highlighted that preliminary health economic analysis done as part of the PALOH trial shows that effective deployment could save NHS resources.

Two experts said minimal training would be needed for staff using the technology, noting that it is similar to other point of care testing currently used in practice. One expert suggested that the technology would need to be made available in every acute setting in which urgent antibiotic treatment is needed.